Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice

in Journal of Endocrinology
Authors:
JW van Neck
Search for other papers by JW van Neck in
Current site
Google Scholar
PubMed
Close
,
NF Dits
Search for other papers by NF Dits in
Current site
Google Scholar
PubMed
Close
,
V Cingel
Search for other papers by V Cingel in
Current site
Google Scholar
PubMed
Close
,
IA Hoppenbrouwers
Search for other papers by IA Hoppenbrouwers in
Current site
Google Scholar
PubMed
Close
,
SL Drop
Search for other papers by SL Drop in
Current site
Google Scholar
PubMed
Close
, and
A Flyvbjerg
Search for other papers by A Flyvbjerg in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

The effects of growth hormone (GH) in regulating the expression of the hepatic and renal GH and insulin-like growth factor (IGF) system were studied by administering a novel GH receptor antagonist (GHRA) (B2036-PEG) at different doses (0, 1.25, 2.5, 5 and 10 mg/kg/day) to mice for 7 days. No differences were observed in the groups with respect to body weight, food consumption or blood glucose. However, a dose-dependent decrease was observed in circulating IGF-I levels and in hepatic and renal IGF-I levels at the highest doses. In contrast, in the 5 and 10 mg/kg/day GHRA groups, circulating and hepatic transcriptional IGF binding protein-3 (IGFBP-3) levels were not modified, likely resulting in a significantly decreased IGF-I/IGFBP-3 ratio. Hepatic GH receptor (GHR) and GH binding protein (GHBP) mRNA levels increased significantly in all GHRA dosage groups. Endogenous circulatory GH levels increased significantly in the 2.5 and 5 mg/kg/day GHRA groups. Remarkably, increased circulating IGFBP-4 and hepatic IGFBP-4 mRNA levels were observed in all GHRA administration groups. Renal GHR and GHBP mRNA levels were not modified by GHRA administration at the highest doses. Also, renal IGFBP-3 mRNA levels remained unchanged in most GHRA administration groups, whereas IGFBP-1, -4 and -5 mRNA levels were significantly increased in the 5 and 10 mg/kg/day GHRA administration groups. In conclusion, the effects of a specific GHR blockade on circulating, hepatic and renal GH/IGF axis reported here, may prove useful in the future clinical use of GHRAs.

 

  • Collapse
  • Expand